The number of disclosed partnerships for academic institutions declined significantly in 2014, down to 278 from 358 in 2013 (457 in 2012). Oncology deals again led the way (56), with neurology (35) and infectious disease (31) following. The large university systems (California and Texas, respectively) were the most active schools (Table 1); the University of Oxford is tied with The Broad Institute with five deals each. AstraZeneca was again the most active pharma, forming 18 partnerships with academic and research institutions (Fig. 1), up from 14 in 2013.

Table 1 Academic partnerships 2014
Figure 1: Most active pharma, biotech with academic/research institutes, 2014.
figure 1

Source: BioCentury.